Clinical data | |
---|---|
Other names | AGN-511; 5-Phenyl-5-(2-piperidylmethyl)barbituric acid |
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H19N3O3 |
Molar mass | 301.346 g·mol |
3D model (JSmol) | |
SMILES
| |
InChI
| |
(what is this?) (verify) |
Prazitone (INNTooltip International Nonproprietary Name, BANTooltip British Approved Name; developmental code name AGN-511) is a barbiturate derivative described as an antidepressant which was developed in the 1960s. Unlike most barbiturates, it has little or no sedative effects, instead acting as a non-sedating anxiolytic and antidepressant. The dosage range in humans is around 200–600 mg, although higher doses have been used in trials for the treatment of depression associated with Parkinson's disease.
References
- ^ Elks, J. (2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer US. p. 1011. ISBN 978-1-4757-2085-3. Retrieved 20 October 2024.
- DE Patent 1645911
- Ross Langlands. Method for imparting anti-depressant and/or anxiolytic effects to animals. US Patent 3,806,596
Anxiolytics (N05B) | |
---|---|
5-HT1ARTooltip 5-HT1A receptor agonists | |
GABAARTooltip GABAA receptor PAMsTooltip positive allosteric modulators |
|
Hypnotics | |
Gabapentinoids (α2δ VDCC blockers) | |
Antidepressants |
|
Antipsychotics | |
Sympatholytics (Antiadrenergics) |
|
Others | |
|
GABAA receptor positive modulators | |
---|---|
Alcohols | |
Barbiturates |
|
Benzodiazepines |
|
Carbamates | |
Flavonoids |
|
Imidazoles | |
Kava constituents | |
Monoureides | |
Neuroactive steroids |
|
Nonbenzodiazepines | |
Phenols | |
Piperidinediones | |
Pyrazolopyridines | |
Quinazolinones | |
Volatiles/gases |
|
Others/unsorted |
|
See also: Receptor/signaling modulators • GABA receptor modulators • GABA metabolism/transport modulators |
This article about an anxiolytic is a stub. You can help Misplaced Pages by expanding it. |